The Pruritus
Therapeutics Market is experiencing significant growth and is projected to
reach a value of over USD 19.98 billion by 2028, with a compound annual growth
rate (CAGR) of approximately 6.2% throughout the forecast period. This growth
can be attributed to the increasing prevalence of skin diseases.
Pruritus, commonly known as itching, is often associated
with primary skin disorders such as atopic dermatitis, xerosis, drug eruptions,
psoriasis, urticaria, arthropod assaults, dermatitis herpetiformis, and
mastocytosis. It manifests as an unpleasant sensation that triggers the urge to
scratch or itch. Pruritus is frequently linked to systemic diseases and can
range in severity from mild itchiness to a persistent, debilitating condition.
Generalized pruritus, based on the underlying causative disease, can be
categorized into various types, including cholestatic pruritus, renal pruritus,
hematologic pruritus, idiopathic generalized pruritus, endocrine pruritus, and
pruritus related to malignancy. Chronic pruritus is commonly observed in
pregnant women, with around 18% of all pregnant women experiencing pruritus.
Competitive
Landscape:
Key players contributing towards the global pruritus
therapeutics market are Allergen,
Bristol-Myers Squibb, Astellas Pharma, GlaxoSmithKline, Eli Lilly, Novartis,
Merck, Sanofi, and Pfizer.
Get
a sample of the report @ https://www.reportsanddata.com/download-free-sample/1176
According to the World Health Organization (WHO), nearly 900
million people worldwide suffer from skin diseases at any given time, making
them one of the most prevalent health issues globally. Atopic dermatitis, also
known as atopic eczema, is a prominent skin disorder characterized by pruritus
and has a prevalence rate of approximately 6.1-22.3% in Western countries. In
the United States, an estimated 23-44 million people are likely to experience
chronic pruritus in the context of both cutaneous and systemic conditions. The
market for skin condition treatments is projected to reach USD 12.6 billion in
terms of revenue, exhibiting a CAGR of 6.5% by 2027, driven by the rising
incidence of skin conditions worldwide.
The prevalence of chronic pruritus significantly impacts
individuals' daily functioning and quality of life. It can lead to mood
disturbances, disrupted sleep patterns, increased anxiety, and depression.
Consequently, pharmaceutical companies are actively developing novel drugs and
treatments to help individuals suffering from chronic skin conditions. For
example, Pfizer Inc., a leading global pharmaceutical company, obtained
approval from the U.S. Food and Drug Administration (FDA) for EUCRISATM
ointment 2% (crisaborole) in 2016. This innovative non-steroidal topical
phosphodiesterase-4 (PDE-4) inhibitor is used for the treatment of mild to
moderate atopic dermatitis.
The growing burden of skin diseases and the detrimental
impact of pruritus on individuals' well-being have spurred the demand for
effective therapeutic options. Continued research and development efforts are
expected to drive advancements in pruritus treatments, providing relief and
improving the quality of life for affected individuals.
To
know more about the report @ https://www.reportsanddata.com/report-detail/pruritus-therapeutics-market
Type (Revenue, USD Million; 2018-2028)
- Corticosteroids
- Antihistamines
- Local Anesthetics
- Counterirritants
- Immunosuppressant
- Calcineurin Inhibitors
- Others
Disease Type (Revenue, USD Million;
2018-2028)
- Skin conditions
- Atopic Dermatitis
- Allergic Contact Dermatitis
- Urticaria
- Others
- Internal diseases
- Nerve disorders
- Psychiatric diseases
- Irritation and allergic reactions
Treatment Type (Revenue, USD Million;
2018-2028)
- Itchy skin treatment
- Corticosteroid creams and ointments
- Other creams and ointments
- Oral medications
End-Use (Revenue, USD Million;
2018-2028)
- Hospital
- Clinic
- Others
Request a
customization of the report @ https://www.reportsanddata.com/request-customization-form/1176
Key Advantages of Pruritus Therapeutics Report:
- Identification
and analysis of the market size and competition
- Qualitative
and quantitative analysis of the market data
- Data
validated by industry experts after extensive primary and secondary
research
- Extensive
regional analysis of the Pruritus Therapeutics industry
- Profiling
of key players along with their business overview, business strategies, deals and
partnerships, and product portfolio
- SWOT and
Porter’s Five Forces Analysis for in-depth understanding of the
competitive landscape
- Feasibility
analysis and investment analysis to enable strategic investment decisions
- Analysis
of opportunities, drivers, restraints, challenges, risks, and limitations
Thank you for reading our report. For
more details please connect with us and our team will ensure the report is
customized to meet all the needs of clients. The report also offers a
comprehensive regional analysis and specific countries can be included in the
report according to the requirements.
About Us:
Reports and Data
is a market research and consulting company that provides syndicated research
reports, customized research reports, and consulting services. Our solutions
purely focus on your purpose to locate, target and analyze consumer behavior
shifts across demographics, across industries and help client’s make a smarter
business decision. We offer market intelligence studies ensuring relevant and
fact-based research across a multiple industries including Healthcare,
Technology, Chemicals, Power and Energy. We consistently update our research
offerings to ensure our clients are aware about the latest trends existent in
the market.
Contact Us:
John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Reports and Data | Web: www.reportsanddata.com
Check our upcoming
research reports @ https://www.reportsanddata.com/upcoming-reports
Visit our blog for more
industry updates @ https://www.reportsanddata.com/blogs